Seki T, Fukuda K. Methods of induced pluripotent stem cells for clinical application. World J Stem Cells 2015; 7(1): 116-125 [PMID: 25621111 DOI: 10.4252/wjsc.v7.i1.116]
Corresponding Author of This Article
Keiichi Fukuda, MD, PhD, FACC, Professor and Chair, Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. kfukuda@a2.keio.jp
Research Domain of This Article
Cell Biology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Stem Cells. Jan 26, 2015; 7(1): 116-125 Published online Jan 26, 2015. doi: 10.4252/wjsc.v7.i1.116
Methods of induced pluripotent stem cells for clinical application
Tomohisa Seki, Keiichi Fukuda
Tomohisa Seki, Keiichi Fukuda, Department of Cardiology, Keio University School of Medicine, Tokyo 160-8582, Japan
Tomohisa Seki, Department of Emergency and Critical Care Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan
Author contributions: Seki T prepared most of the paper; Fukuda K provided advice and proofread the paper.
Supported by The Support Program to break the bottlenecks at R&D Systems for accelerating the practical use of Health Research Outcome, the Highway Program for the Realization of Regenerative Medicine, and Health Labour Sciences Research Grant.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Keiichi Fukuda, MD, PhD, FACC, Professor and Chair, Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. kfukuda@a2.keio.jp
Telephone: +81-3-53633874 Fax: +81-3-53633875
Received: July 27, 2014 Peer-review started: July 28, 2014 First decision: September 4, 2014 Revised: September 18, 2014 Accepted: October 23, 2014 Article in press: December 16, 2014 Published online: January 26, 2015
Abstract
Reprograming somatic cells using exogenetic gene expression represents a groundbreaking step in regenerative medicine. Induced pluripotent stem cells (iPSCs) are expected to yield novel therapies with the potential to solve many issues involving incurable diseases. In particular, applying iPSCs clinically holds the promise of addressing the problems of immune rejection and ethics that have hampered the clinical applications of embryonic stem cells. However, as iPSC research has progressed, new problems have emerged that need to be solved before the routine clinical application of iPSCs can become established. In this review, we discuss the current technologies and future problems of human iPSC generation methods for clinical use.
Core tip: Each induced pluripotent stem cells methodology has advantages and disadvantages, as in the case of autologous vs allogenic transplantation, and the choice of appropriate strategy may vary depending on the intended use. Additionally, to avoid tumorigenesis and to establish effective differentiation into the intended cells, further investigation is needed to identify the most suitable iPSC line and how these lines should be selected.
